An outbreak of monkeypox made their heads itch. What could 2022 bring to the market? We’ve seen a stock market crash, a hoped-for recovery from COVID-19, record inflation, a rate hike, and now this one. But it put some small arrows in focus.
On Wednesday, the World Health Organization confirmed that there are more than 550 cases of monkeypox in 30 countries. Now on a global scale, this is the latest virus to strike some fear into the hearts of investors who had to endure the pain of the last pandemic just a few years ago.
One major concern is that even the World Health Organization does not know how to measure outbreaks. During a press conference this week, Dr. Rosamund Lewis, technical officer of monkeypox, said, “We don’t really know if it’s too late to contain the disease. What the WHO and all member states are trying to do is prevent the spread of the disease.”
Meanwhile, WHO Director-General Tedros Adhanom Ghebreyesus has already tried to allay concerns. The Director-General recently explained that the global appearance of monkeypox indicates that it has been spreading undetected for some time outside of Africa. Tedros also said that most symptoms generally go away on their own. Although in some cases, the virus can be more severe.
Stocks for monkeypox to watch
Because there are close ties to the smallpox virus, some look for opportunities to look for stocks of companies working on candidate vaccines. For anyone trading small stocks, the latest headline from Tonix Pharmaceuticals (NASDAQ: TNXP) shows how news can act as an important catalyst. Shares were already on the rise after the share buyback plan was announced. On Wednesday, the company also announced the issuance of a patent for the smallpox and smallpox vaccine, TNX-801.
[Read More] Why these three penny stocks rose today
Another one of the monkeypox stocks that is setting the tone in the stock market today is SIGA Technologies (NASDAQ:SIGA). The company’s stock has been moving since traders began following developments in the SIGA Tpoxx Smallpox platform and its potential application to monkeypox.
Other monkeypox stocks were not done justice as well as TNXP and SIGA stocks. For example, Bavarian Nordic Corporation (OTC: BVNRY) has received applications for the JYNNEOS® smallpox vaccine from the US Biomedical Advanced Research and Development Authority (BARDA). This will allow the first doses of this version to be manufactured and billed in 2023 and 2024. According to headlines this week, the options are valued at $119 million and “the first options being exercised to convert the bulk vaccine… into lyophilized” doses of a vaccine JYNNEOS Smallpox. “
Despite this, BVNRY shares did not react favorably in the stock market. In fact, since May 20, the stock has fallen from a high of $11.70 to $9.23 this week.
Monkeypox Penny Watch List Stock for June
1. GeoVax Labs, Inc. (NASDAQ: GOVX)
GeoVax (GOVX Stock Report) is developing vaccines and immunotherapies and has been in the spotlight for monkeypox stock hunters for the past few weeks. We discussed this in our late May list of monkeypox stocks to watch. That’s where the corner comes into play with GeoVax’s GV-MVA-VLPTM platform. It is used to build candidate vaccines using genetic sequences from viruses. A statement released earlier this year is back in focus thanks to GeoVax’s chief scientific officer, Farshad Guirakhoo, PhD. He said the GeoVax platform specifically mentioned smallpox and monkeypox.
[Read More] Hot penny stock to watch it climb now
“Perhaps importantly, the viral basis vector of the vaccine (MVA) has more than 50 years of safety records and was recently approved by the US Food and Drug Administration for the prevention of smallpox and monkeypox diseases,” explained Dr. Geraho.
The company also recently presented at the Genetic Vaccine Development Summit for Infectious Diseases on May 26. This offer was made a few days before GeoVax released a tweet that had a strong market resonance. “Previous peer-reviewed publications have demonstrated that GeoVax formulations for MVA also provide protection against monkeypox,” the company’s May 31 tweet said.
As the rest of the short week approaches, GOVX stock could remain one to watch if monkeypox cases continue to rise.
2. Chimerix (NASDAQ: CMRX)
LIke Bavarian Nordic, Chimerix (CMRX stock report) is muted during the monkeypox explosion in the stock market. One reason for optimism over optimism is its stripping of the company’s only marketed product. Emergent BioSolutions Inc. (NYSE:EBS), another one of the monkeypox stocks to watch, the exclusive worldwide rights to Chimerix’s Tembexa. This is the first FDA-approved antiviral for all age groups for smallpox.
Thanks to the close association of viruses, smallpox stocks are being monitored as potential monkeypox vaccine developers. “This transaction expands and diversifies our business in medical countermeasures with the addition of small-molecule therapy aligned with the government’s smallpox preparedness strategy,” Paul Williams, senior vice president of government/MCM business at Emergent, said in the May update.
Part of the deal includes a 20% royalty on Tembexa’s future gross profit in the United States associated with volumes over 1.7 million treatment cycles. Chimerix also said it could take a 15% royalty on gross profit outside the United States associated with sales of the drug in the exclusivity period on a market-to-market basis. Next week, the company will give an overview of the company at the Jefferies Healthcare conference on June 8.
3. Aethlon Medical, Inc. (NASDAQ: AEMD)
Aethlon’s treatment pipeline (AEMD Stock Report) is designed to target various organ-threatening diseases. For example, Hemopurifier has been studied as an active platform to combat future COVID-19 variants that could affect the efficacy of some vaccines. The device has been awarded the status of a “breakthrough device” in the treatment of patients with metastatic cancer. Furthermore, the Investigational Device exemption was granted in 2019 for cancer and also updated to include a clinical study of patients with viral infections, including COVID.
[Read More] How to make money with penny stocks
Where does monkeypox come from? Aethlon claims that “preclinical Hemopurifier studies have validated capture of a wide range of viral threats. These include: chikungunya, dengue and West Nile virus, as well as vaccinia and monkeypox, which serve as models for human smallpox infection.”
Like the others on this list of small stocks, more monkeypox titles could put some of these names on the radar this week.
Will monkeypox become the size of COVID? This has yet to be seen, and so far (fortunately), it hasn’t. However, as in the early days of the pandemic, the data is only just beginning to emerge. Speculation has become a driving force for traders, given the current uncertainty. As such, it is essential to realize this and ensure that an appropriate strategy is developed.
Stock monkey pox to watch
|Code||The Company’s name|
|Electronically Controlled Brake System (EBS)||Emergent Biosolutions Inc.|
|GOVX||GeoVax Inc. Labs.|
|win||Tonix Pharmaceuticals Holding Corp.|
|AEMD||Athlon Medical Company|